United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)

Published on October 20, 2021

United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

Continue reading on website
Other news

How to use CoDi® and grow your business? We invite you to find out at Entrepreneur Homeschool

October 20, 2021
Pay and collect from your cell phone easily, safely, quickly and without commissions 24 hours a day. We invite you to get to know CoDi®, the Banxico tool that will allow you to optimize your business operations. The appointment is this October 21 at 7:00 pm

Dividend King Dover Corporation Raises Guidance 

October 20, 2021
While still impacted by the global supply chain issues, early cycle companies like Dover Corporation are proving to be better positioned for the supply chain crunch. The supply chain crunch...